ES8707295A1 - Procedimiento para la obtencion de anticuerpos monoclonales - Google Patents

Procedimiento para la obtencion de anticuerpos monoclonales

Info

Publication number
ES8707295A1
ES8707295A1 ES542017A ES542017A ES8707295A1 ES 8707295 A1 ES8707295 A1 ES 8707295A1 ES 542017 A ES542017 A ES 542017A ES 542017 A ES542017 A ES 542017A ES 8707295 A1 ES8707295 A1 ES 8707295A1
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
renin
hybridoma cells
derivatives
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES542017A
Other languages
English (en)
Other versions
ES542017A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8707295A1 publication Critical patent/ES8707295A1/es
Publication of ES542017A0 publication Critical patent/ES542017A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/86—Renin inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PROCEDIMIENTO PARA OBTENER ANTICUERPOS MONOCLONALES. COMPRENDE: A) CULTIVAR A LAS CELULAS DE HIBRIDOMA PRODUCTORAS DE ANTICUERPOS MONOCLONALES; B) PRECIPITAR AL SOBRENADANTE DEL CULTIVO CON SULFATO AMONICO; Y C) PURIFICAR EL PRECIPITADO POR CROMATOGRAFIA, PARA OBTENER ANTICUERPOS MONOCLONADOS. LOS ANTICUERPOS MONOCLONALES SE ELIGEN ENTRE ANTICUERPO MONOCLONAL R 3-36-16 Y ANTICUERPO MONOCLONAL MARCADO 125I. SE UTILIZAN CONTRA LA RENINA HUMANA.
ES542017A 1984-04-09 1985-04-08 Procedimiento para la obtencion de anticuerpos monoclonales Expired ES8707295A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH178184 1984-04-09

Publications (2)

Publication Number Publication Date
ES8707295A1 true ES8707295A1 (es) 1987-07-16
ES542017A0 ES542017A0 (es) 1987-07-16

Family

ID=4218460

Family Applications (2)

Application Number Title Priority Date Filing Date
ES542017A Expired ES8707295A1 (es) 1984-04-09 1985-04-08 Procedimiento para la obtencion de anticuerpos monoclonales
ES557016A Expired ES8802254A1 (es) 1984-04-09 1986-08-14 Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557016A Expired ES8802254A1 (es) 1984-04-09 1986-08-14 Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana.

Country Status (13)

Country Link
US (1) US4780401A (es)
EP (1) EP0158599B1 (es)
JP (2) JPH0669390B2 (es)
AT (1) ATE57392T1 (es)
AU (1) AU591870B2 (es)
CA (1) CA1277261C (es)
DE (1) DE3580056D1 (es)
DK (1) DK165326C (es)
ES (2) ES8707295A1 (es)
FI (1) FI87933C (es)
IE (1) IE57956B1 (es)
NO (1) NO165556C (es)
ZA (1) ZA852557B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
AU4250893A (en) * 1992-05-14 1993-12-13 L.R.S. Diagnostics, Inc. Methods and novel proteins associated with low renin syndrome
EP0606516B1 (en) * 1993-01-13 1998-12-30 Idemitsu Kosan Company Limited Anti-human ceruloplasmin monoclonal antibody
WO1994020857A1 (en) * 1993-03-11 1994-09-15 The Regents Of The University Of California Assay for humoral immunity to macromolecules
US6911528B1 (en) * 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US20030167483A1 (en) * 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
ES2375268T3 (es) 2000-12-14 2012-02-28 The Brigham And Women's Hospital, Inc. Marcadores inflamatorios para la detección y prevención de diabetes mellitus.
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
AU2004270162B2 (en) * 2003-08-28 2010-05-13 Nicox S.A. Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
AU2004315596B2 (en) 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US9164104B2 (en) 2004-10-06 2015-10-20 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
JP2008520578A (ja) * 2004-11-15 2008-06-19 ニトロメッド インコーポレーティッド 複素環式の酸化窒素供与体基を含む利尿化合物、組成物および使用方法
WO2006078995A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
WO2007086884A2 (en) * 2005-02-16 2007-08-02 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
US20090012057A1 (en) * 2005-02-28 2009-01-08 Nitromed, Inc. Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use
WO2006099058A2 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EP1982711A1 (en) 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
US20090018091A1 (en) * 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
CA2624933A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
US20080293702A1 (en) * 2005-12-22 2008-11-27 Nitromed, Inc. Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US7897360B2 (en) * 2006-12-15 2011-03-01 Kimberly-Clark Worldwide, Inc. Enzyme detection techniques
WO2008131224A2 (en) 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2531163A1 (en) 2010-02-01 2012-12-12 The Hospital For Sick Children Remote ischemic conditioning for treatment and preventon of restenosis
CA2795053A1 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
EP2855458B1 (en) 2012-05-11 2018-08-08 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
ES2786506T3 (es) 2012-08-01 2020-10-13 Zahra Tavakoli Composiciones congeladas fluidas que comprenden un agente terapéutico
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
CN110114676B (zh) * 2016-10-21 2022-03-25 富士瑞必欧株式会社 肾素浓度的免疫学测定方法
CN107007849A (zh) * 2017-06-19 2017-08-04 河北省人民医院 一种建立甲减性心功能不全大鼠动物模型的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies

Also Published As

Publication number Publication date
IE57956B1 (en) 1993-05-19
AU591870B2 (en) 1989-12-21
DE3580056D1 (de) 1990-11-15
CA1277261C (en) 1990-12-04
ZA852557B (en) 1985-11-27
ES542017A0 (es) 1987-07-16
US4780401A (en) 1988-10-25
EP0158599A2 (de) 1985-10-16
EP0158599B1 (de) 1990-10-10
DK165326B (da) 1992-11-09
EP0158599A3 (en) 1987-12-16
JPH0669390B2 (ja) 1994-09-07
DK153385D0 (da) 1985-04-03
JPS60231624A (ja) 1985-11-18
NO165556B (no) 1990-11-19
ES8802254A1 (es) 1988-04-16
NO851384L (no) 1985-10-10
FI851334L (fi) 1985-10-10
DK165326C (da) 1993-03-29
ES557016A0 (es) 1988-04-16
FI87933C (fi) 1993-03-10
DK153385A (da) 1985-10-10
AU4088685A (en) 1985-10-17
ATE57392T1 (de) 1990-10-15
FI851334A0 (fi) 1985-04-03
JPH0669371B2 (ja) 1994-09-07
IE850876L (en) 1985-10-09
JPS6485070A (en) 1989-03-30
FI87933B (fi) 1992-11-30
NO165556C (no) 1991-02-27

Similar Documents

Publication Publication Date Title
ES8802254A1 (es) Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana.
DE3274951D1 (en) Composite semipermeable membrane, process for its production, and method of its use
IL73883A (en) Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
ES8307263A1 (es) Un procedimiento para la preparacion de fosfonamidas sustituidas.
ES2007341A6 (es) Un procedimiento para producir m-csf
HUT37410A (en) Process for the production of benzothiazole- and benzothiophene-derivatives, as well as of therapeutic preparations containing them as agent
EP0222330A3 (en) N6-substituted-5'-oxidized adenosine analogs
ES8606396A1 (es) Procedimiento para la preparacion de activadores de plasmi- nogeno de tejidos
EP0232061A3 (en) High-strength steel for valve springs process for producing the steel, and valve springs made of the same
PT83255A (en) Process for the preparation of polypeptides and characteristic antibodies of papillomavirus and diagnostic method thereto
EP0179483A3 (en) Method for preparing monoclonal antibodies to hbsag
HUT40436A (en) Process for production pirrolo-benzimidasoles and medical preparatives containing thereof
IE851295L (en) Monoclonal human mif
EP0102601A3 (en) Monoclonal antibody, a process for its production and the use of this monoclonal antibody
ES8605812A1 (es) Procedimiento para obtener un preparado de factor xiii
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
HUT45035A (en) Process for producing thiazolone derivatives
ES8707565A1 (es) Un procedimiento para producir un anticuerpo monoclonal
SE8404334D0 (sv) 16-fluoro-16,17-didehydro-prostanoids and process for their preparation
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
HUT34051A (en) Process for contuonisly ensimatic transformation of alfa hydroxicarbonacids to suitable, optically active alpha aminocarbonacids
PT80145A (en) Process for preparing spiro-indenes and spiro-1,2-dihydro-naftalenes useful for treatment of diabetic complications
PT80996A (en) Process for preparing 6-fluoro-chroman-4-carboxylic acid derivatives
MD48C2 (ro) Procedeu de purificare a b-interferonei umane
HUT37626A (en) Process for common production of l-hydroxi-methan-dishosphric acid and nitrilo-tri/methilene-phosphoric acid/

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20000201